Smith & Nephew SNATS (SNN) Expected to Announce Quarterly Earnings on Tuesday

Smith & Nephew SNATS (NYSE:SNN) is projected to issue its Q2 2026 resultson Tuesday, August 4th. Analysts expect the company to announce earnings of $0.94 per share and revenue of $1.64 billion for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 6:30 AM ET.

Smith & Nephew SNATS Trading Up 1.9%

NYSE:SNN opened at $31.14 on Tuesday. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS has a 12 month low of $28.56 and a 12 month high of $38.79. The company has a 50 day simple moving average of $30.30 and a two-hundred day simple moving average of $32.23.

Wall Street Analyst Weigh In

A number of analysts have commented on SNN shares. Sanford C. Bernstein set a $31.85 target price on shares of Smith & Nephew SNATS in a report on Monday, May 11th. Canaccord Genuity Group dropped their price target on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. Kepler Capital Markets downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research report on Thursday, June 4th. The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Finally, Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 4th. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Smith & Nephew SNATS has a consensus rating of “Hold” and a consensus price target of $30.93.

Institutional Investors Weigh In On Smith & Nephew SNATS

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNN. Arax Advisory Partners lifted its holdings in Smith & Nephew SNATS by 142.6% during the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 569 shares in the last quarter. Advisors Asset Management Inc. bought a new position in shares of Smith & Nephew SNATS in the fourth quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Smith & Nephew SNATS in the third quarter worth $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Smith & Nephew SNATS in the fourth quarter worth $43,000. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Smith & Nephew SNATS by 105.8% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 1,385 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 712 shares in the last quarter. Institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.